MaxCyte, Inc. (MXCT) Operating Margin
- Operating margin · 12 months: Value -221.98%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -221.98% | Operating income / revenue. Period ending 2026-06-30. $-41.79M ÷ $18.83M × 100 ≈ -221.98% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -41.79M USD | Operating Income (Loss) |
| Revenue | 18.83M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.45M USD | Cost of Goods and Services Sold |
| Research and development | 16.76M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-41.79M | $18.83M | $6.45M | $16.76M | (m) | -221.98% |
| 2026-03-31 | $-45.79M | $19.71M | $6.29M | $18.78M | (m) | -232.24% |
| 2025-12-31 | $-51.90M | $20.96M | $6.22M | $20.82M | (m) | -247.64% |
| 2025-09-30 | $-53.57M | $22.23M | $6.89M | $22.10M | (m) | -241.04% |
| 2025-06-30 | $-53.48M | $23.23M | $7.22M | $22.10M | (m) | -230.16% |
| 2025-03-31 | $-51.22M | $22.37M | $7.19M | $21.45M | (m) | -228.91% |
| 2024-12-31 | $-51.20M | $22.21M | $7.10M | $22.23M | (m) | -230.46% |
| 2024-09-30 | $-46.39M | $20.92M | $6.39M | $23.45M | (m) | -221.80% |
| 2024-06-30 | $-46.29M | $19.46M | $5.26M | $24.40M | (m) | -237.88% |
| 2024-03-31 | $-47.40M | $20.12M | $5.14M | $24.45M | (m) | -235.60% |
| 2023-12-31 | $-48.30M | $19.50M | $4.74M | $23.82M | (m) | -247.73% |
| 2023-09-30 | $-46.95M | $22.50M | $4.72M | $23.70M | (m) | -208.69% |
| 2023-06-30 | $-40.71M | $25.50M | $5.29M | $22.76M | (m) | -159.69% |
| 2023-03-31 | $-36.38M | $26.86M | $5.04M | $21.80M | (m) | -135.46% |
| 2022-12-31 | $-27.36M | $28.75M | $5.10M | $19.51M | (m) | -95.17% |
| 2022-09-30 | $-25.57M | $28.50M | $4.78M | $17.17M | (m) | -89.71% |
| 2022-06-30 | $-20.30M | $26.95M | $4.35M | $14.59M | (m) | -75.30% |
| 2022-03-31 | $-15.97M | $24.19M | $4.02M | $13.10M | (m) | -66.04% |
| 2021-12-31 | $-18.19M | $21.57M | $3.65M | $15.41M | (m) | -84.32% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-11.06M | $15.45M | $2.77M | $17.73M | (m) | -71.56% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-12.42M | $13.26M | $2.50M | $17.59M | (m) | -93.68% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |